BACKGROUND: We lack simple and reliable diagnostic tools to predict pathological staging as well as further progression of prostate cancer in individual cases. METHODS: We studied deletions on 8p (8p22 and 8p23-pter), 10q (10q24-qter), and 16q (16q24) by fluorescence in situ hybridization in 53 specimens from patients with prostate cancer, and compared the status of these deletions with various clinical parameters. Forty-five cases were further evaluated regarding disease progression with a median follow-up period of 62 months. RESULTS: The overall frequencies of deletions for 8p, 10q, and 16q were 74, 55, and 55%, respectively. The frequency of 8p and 16q deletions increased significantly in parallel with tumor grade (P < 0.01 and < 0.05, respectively), while that of 10q deletions did not. Patients whose tumors showed 8p22 deletions had a significantly higher frequency in pT3 or metastatic tumors than in pT2 tumors. Patients whose tumors showed both 8p22 and 16q24 deletions had a significantly higher frequency of nodal metastases than non-metastases. A Cox hazard proportional model revealed 8p22 deletion to be the strongest parameter predictive of disease progression (hazard ratio = 6.624; P = 0.0001). CONCLUSION: Estimation of 8p22 and 16q24 deletions may serve as a genetic diagnosis for predicting pathological staging as well as disease progression in prostate cancer. Copyright 2002 Wiley-Liss, Inc.
BACKGROUND: We lack simple and reliable diagnostic tools to predict pathological staging as well as further progression of prostate cancer in individual cases. METHODS: We studied deletions on 8p (8p22 and 8p23-pter), 10q (10q24-qter), and 16q (16q24) by fluorescence in situ hybridization in 53 specimens from patients with prostate cancer, and compared the status of these deletions with various clinical parameters. Forty-five cases were further evaluated regarding disease progression with a median follow-up period of 62 months. RESULTS: The overall frequencies of deletions for 8p, 10q, and 16q were 74, 55, and 55%, respectively. The frequency of 8p and 16q deletions increased significantly in parallel with tumor grade (P < 0.01 and < 0.05, respectively), while that of 10q deletions did not. Patients whose tumors showed 8p22 deletions had a significantly higher frequency in pT3 or metastatic tumors than in pT2 tumors. Patients whose tumors showed both 8p22 and 16q24 deletions had a significantly higher frequency of nodal metastases than non-metastases. A Cox hazard proportional model revealed 8p22 deletion to be the strongest parameter predictive of disease progression (hazard ratio = 6.624; P = 0.0001). CONCLUSION: Estimation of 8p22 and 16q24 deletions may serve as a genetic diagnosis for predicting pathological staging as well as disease progression in prostate cancer. Copyright 2002 Wiley-Liss, Inc.
Authors: Francesca Demichelis; Sunita R Setlur; Rameen Beroukhim; Sven Perner; Jan O Korbel; Christopher J Lafargue; Dorothee Pflueger; Cara Pina; Matthias D Hofer; Andrea Sboner; Maria A Svensson; David S Rickman; Alex Urban; Michael Snyder; Matthew Meyerson; Charles Lee; Mark B Gerstein; Rainer Kuefer; Mark A Rubin Journal: Genes Chromosomes Cancer Date: 2009-04 Impact factor: 5.006
Authors: Simon Hughes; Maisa Yoshimoto; Ben Beheshti; Richard S Houlston; Jeremy A Squire; Andrew Evans Journal: BMC Genomics Date: 2006-03-30 Impact factor: 3.969
Authors: René Böttcher; Charlotte F Kweldam; Julie Livingstone; Emilie Lalonde; Takafumi N Yamaguchi; Vincent Huang; Fouad Yousif; Michael Fraser; Robert G Bristow; Theodorus van der Kwast; Paul C Boutros; Guido Jenster; Geert J L H van Leenders Journal: BMC Cancer Date: 2018-01-02 Impact factor: 4.430